| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/06/2006 | EP1727545A1 Use of n-piperidine derivatives for the treatment of neurodegenerative pathologies |
| 12/06/2006 | EP1727544A1 Use of indazolecarboxamide derivatives for the preparation of a medicament that is intended for the treatment and prevention of paludism |
| 12/06/2006 | EP1727543A1 Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders |
| 12/06/2006 | EP1727542A2 Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor |
| 12/06/2006 | EP1727541A1 Imidazole-based hmg-coa reductase inhibitors |
| 12/06/2006 | EP1727540A1 Melanin-concentrating hormone receptor antagonists and methods of use |
| 12/06/2006 | EP1727539A1 Use of rotigotine for treating and preventing parkinson's plus syndrome |
| 12/06/2006 | EP1727538A2 Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders |
| 12/06/2006 | EP1727537A2 Use of beta-lapachone for treating or preventing cancer |
| 12/06/2006 | EP1727536A1 Beta-lapachone and s-phase drug combinations for cancer treatment |
| 12/06/2006 | EP1727535A1 Combinations comprising alpha-2-delta ligands |
| 12/06/2006 | EP1727534A2 Hydroxymethylbutyrate compositions and uses thereof |
| 12/06/2006 | EP1727533A1 Use of cysteinyl leukotriene 2 receptor antagonists |
| 12/06/2006 | EP1727532A2 Chemically stable compositions of 4-hydroxy tamoxifen |
| 12/06/2006 | EP1727531A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
| 12/06/2006 | EP1727530A2 Topical formulations for the treatment of skin conditions |
| 12/06/2006 | EP1727529A2 Prevention of retinopathy by inhibition of the visual cycle |
| 12/06/2006 | EP1727528A2 Inhibition of mixed lineage kinases and uses therefor |
| 12/06/2006 | EP1727527A1 Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain |
| 12/06/2006 | EP1727526A2 Piperazine urea derivatives for the treatment of endometriosis |
| 12/06/2006 | EP1727524A1 Preparation of lipid coated cefuroxime axetil |
| 12/06/2006 | EP1727523A2 Pharmaceutical formulation containing unmilled flutamide |
| 12/06/2006 | EP1727522A2 Cosmetic and pharmaceutical foam with solid matter |
| 12/06/2006 | EP1727521A1 Bioavailable nutritional supplement and method of treatment of malabsorption |
| 12/06/2006 | EP1727520A2 Method of preparation of mixed phase co-crystals with active agents |
| 12/06/2006 | EP1727421A2 Animal cover having a temperature altering device |
| 12/06/2006 | EP1684739A4 Treatment and prevention of liver disease associated with parenteral nutrition (pn) |
| 12/06/2006 | EP1631146A4 Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments |
| 12/06/2006 | EP1615632B1 Floating oral formulations for controlled release of betaine |
| 12/06/2006 | EP1608755A4 Tak1-mediated inhibition of osteogenesis |
| 12/06/2006 | EP1601339A4 Skin peeling composition and method |
| 12/06/2006 | EP1505066B1 Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic |
| 12/06/2006 | EP1487462A4 Preparations for topical skin use and treatment |
| 12/06/2006 | EP1480667B1 Compositions comprising pulmonary surfactants and a polymyxin having improved surface properties |
| 12/06/2006 | EP1458369B1 Gel comprising at least a retinoid and benzoyl peroxide |
| 12/06/2006 | EP1456212B1 6-aminomorphinane derivatives, method for the production and use thereof |
| 12/06/2006 | EP1446128B1 Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| 12/06/2006 | EP1438304B1 Novel substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists |
| 12/06/2006 | EP1408897A4 Gum resin as a carrier for topical application of pharmacologically active agents |
| 12/06/2006 | EP1397135B1 Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways |
| 12/06/2006 | EP1368319B1 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 12/06/2006 | EP1345610B1 Quetiapine for treating of dyskinesia in non-psychotic patients |
| 12/06/2006 | EP1339282A4 Hydrophilic polymer blends used for dry cow therapy |
| 12/06/2006 | EP1318977B1 Substituted phenylcyclohexane carboxylic acid amides and the use thereof |
| 12/06/2006 | EP1315481B1 Medicament for treating intestinal diseases |
| 12/06/2006 | EP1313459B1 Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents |
| 12/06/2006 | EP1291343B1 Hydroxyformamidine derivatives and medicines containing the same |
| 12/06/2006 | EP1270577B1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 12/06/2006 | EP1221975B1 Polymer stabilized neuropeptides |
| 12/06/2006 | EP1220839B1 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors |
| 12/06/2006 | EP1218381B1 AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES |
| 12/06/2006 | EP1212050B1 Formulations containing tetracyclines for treating or preventing mucositis |
| 12/06/2006 | EP1210086B1 Use of halofuginone for treating urethral stricture |
| 12/06/2006 | EP1165078B1 Methods of inducing cancer cell death and tumor regression |
| 12/06/2006 | EP1137411B1 Palladium-substituted bacteriochlorophyll derivatives and use thereof |
| 12/06/2006 | EP1119360B1 Compositions for increasing intestinal absorption of fats |
| 12/06/2006 | EP1091738B1 BICYCLIC sPLA 2 INHIBITORS |
| 12/06/2006 | EP1079819B1 Hydroxamic acid derivatives as antibacterials |
| 12/06/2006 | EP1069893B1 Use of dexmedetomidine for icu sedation |
| 12/06/2006 | EP1044006B1 Use of an antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection |
| 12/06/2006 | EP0969865B1 Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
| 12/06/2006 | EP0948334B1 Method of treating prostatic diseases using active vitamin d analogues |
| 12/06/2006 | EP0935667B1 Process for preparing docosahexaenoic acid and docosapentaenoic acid |
| 12/06/2006 | EP0915871B1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 12/06/2006 | EP0910406B1 Recombinant canine herpesviruses |
| 12/06/2006 | EP0837934B1 Human vascular endothelial growth factor 2 |
| 12/06/2006 | EP0740701B1 Mammalian monocyte chemoattractant protein receptors |
| 12/06/2006 | CN2843449Y Externally-applied plaster for treating acute sprain and contuse |
| 12/06/2006 | CN1875275A Biomarkers for the prediction of drug-induced diarrhoea |
| 12/06/2006 | CN1875271A Treating neuropathic pain with neuropeptide FF receptor 2 agonists |
| 12/06/2006 | CN1875039A Method of manufacture of polyacrolein |
| 12/06/2006 | CN1875031A Acremonic acid derivatives |
| 12/06/2006 | CN1875030A Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases |
| 12/06/2006 | CN1875023A Use of thienopyrimidines |
| 12/06/2006 | CN1875022A Tocopherol-modified therapeutic drug compounds |
| 12/06/2006 | CN1875021A Substituted naphthyridinone derivatives |
| 12/06/2006 | CN1875020A Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same |
| 12/06/2006 | CN1875019A Novel crystalline anhydride with anticholinergic effect |
| 12/06/2006 | CN1875017A Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound |
| 12/06/2006 | CN1875016A 咪唑衍生物 Imidazole derivatives |
| 12/06/2006 | CN1875015A Benzo [b][1,4] dioxepine derivatives |
| 12/06/2006 | CN1875012A 2-phenylbenzofuran derivatives, a process for preparing them, and their use |
| 12/06/2006 | CN1875008A Process for preparation of rosuvastatin calcium |
| 12/06/2006 | CN1875005A Malonamide derivatives blocking the activtiy of gamma-secretase |
| 12/06/2006 | CN1875004A Resolution of a narwedine amide derivative |
| 12/06/2006 | CN1875001A Benzannelated compounds as PPAR activators |
| 12/06/2006 | CN1874998A 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]-methyl piperidine oxalate (donepezil oxalate) and its polymorphs |
| 12/06/2006 | CN1874996A Aminopropanol derivatives |
| 12/06/2006 | CN1874992A Resolution of 3-amino alkylnitriles |
| 12/06/2006 | CN1874991A Compound capable of binding S1P receptor and pharmaceutical use thereof |
| 12/06/2006 | CN1874959A Methods and articles for maintaining hydantoinylated polymers in a biocidally active state |
| 12/06/2006 | CN1874791A Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
| 12/06/2006 | CN1874781A Compositions of botanical extracts for cancer therapy |
| 12/06/2006 | CN1874780A Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemot |
| 12/06/2006 | CN1874779A Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia |
| 12/06/2006 | CN1874778A Pharmaceutical formulation comprising a pyrimidine-A-one derivative coated with an enteric polymer |
| 12/06/2006 | CN1874777A 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| 12/06/2006 | CN1874776A 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
| 12/06/2006 | CN1874775A 4-fluoro-4-(pyridin-2-yl)-piperidine-1-carboxamide derivatives and related compounds which modulate the function of the vanilloid-1 receptor (VR1) for the treatment of pain |
| 12/06/2006 | CN1874774A Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |